Nov. 11, 2020 — On 11 November the University of Cambridge announced a five-year agreement with AstraZeneca and GSK to fund the Cambridge Centre for AI in Medicine (CCAIM). For the 5-year duration, AstraZeneca and GSK will support five new PhD studentships per year. This program will enable the best and brightest young minds in machine learning and bioscience to partner with leaders in industry and academia, wherever they may be in the world.
CCAIM has been set up as a cutting-edge research group. Its faculty of 10 University of Cambridge researchers – in addition to world-class PhD students, currently